EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Voyager Therapeutics's enterprise value is $193.9 Mil.
Voyager Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $250.0 Mil. Therefore, Voyager Therapeutics's EV-to-Revenue for today is 0.78.
The historical rank and industry rank for Voyager Therapeutics's EV-to-Revenue or its related term are showing as below:
VYGR'
s EV-to-Revenue Range Over the Past 10 Years
Min: 0.07 Med: 4.21 Max: 77.84
Current: 0.78
During the past 11 years, the highest EV-to-Revenue of Voyager Therapeutics was 77.84. The lowest was 0.07. And the median was 4.21.
VYGR's EV-to-Revenue is ranked better than 87.8% of 1033
companies
in the Biotechnology industry
Industry Median: 7.68
vs VYGR: 0.78
Voyager Therapeutics EV-to-Revenue Historical Data
The historical data trend for Voyager Therapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Voyager Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, Voyager Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Voyager Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Voyager Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Voyager Therapeutics's EV-to-Revenue falls into.
Voyager Therapeutics's current Enterprise Value is $193.9 Mil.
Voyager Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $250.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Voyager Therapeutics's share price for today is $7.54.
Voyager Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.57.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Voyager Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Voyager Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Voyager Therapeutics (Voyager Therapeutics) Business Description
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. The company operates in a single segment of developing and commercializing gene therapies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VYGR has been successfully added to your 